The THAP11 antibody is a crucial tool for studying the THAP domain-containing protein 11 (THAP11), a transcription factor involved in regulating gene expression, cell proliferation, and differentiation. THAP11 belongs to the THAP family, characterized by a conserved zinc-coordinating THAP domain at the N-terminus that binds DNA, and a C-terminal region mediating protein interactions. It acts as a transcriptional repressor, modulating targets linked to cell cycle control, apoptosis, and metabolic pathways. THAP11 is implicated in embryonic development, stem cell maintenance, and oncogenesis, with roles in suppressing oncogenes or acting as a tumor suppressor in certain cancers.
The antibody specifically detects THAP11 in applications like Western blotting, immunohistochemistry, and immunofluorescence, enabling researchers to analyze its expression, localization, and interactions in cellular and tissue contexts. Studies using THAP11 antibodies have revealed its dysregulation in cancers (e.g., colorectal carcinoma), neurological disorders, and metabolic diseases, highlighting its therapeutic potential. Additionally, THAP11 interacts with chromatin-modifying complexes (e.g., Polycomb repressors), offering insights into epigenetic regulation. Available as monoclonal or polyclonal variants, these antibodies are vital for exploring THAP11's roles in development, disease mechanisms, and regenerative medicine.